Royalty Pharma plc (RPRX)
$56.93+1.28%Close
SELLBEAR · day 22
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $24.5B
- Beta
- 0.43
- Div yield
- 1.64%
- P/E (TTM)
- 23.42
- Short % float
- 3.12%
- Days to cover
- 4.4
- SI change
- +10.6%
- 1W
- -0.40%
- 1M
- -3.10%
- vs SPY 1W
- -1.56%
- vs SPY 1M
- -6.09%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 62
- VALUE
- 38
- GROWTH
- 51
- GARP
- 48
- TYPE
- Dividend Compounder
Composite of Value · Growth · GARP
ROIC7.4%
REV YoY-
ROE12.3%
EPS YoY-
ROA4.1%
GROSS89
OP62
NET32
[VALUATION]
P/E TTM23.42
P/E FWD11.14
SECTOR PE20.47
INDUSTRY PE108.47
P/B3.68
P/FCF-
EV/EBITDA19.33
EV/EBIT-
PEG1.52
FCF YIELD-
RISK
INT COV-
D/E131.16
ALTMAN Z-
CURR RATIO1.29
ND/EBITDA-
BETA0.43
Company news
FAQ
- What is LOPJLB’s current signal on RPRX?
- LOPJLB’s latest quantitative signal on Royalty Pharma plc (RPRX) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is RPRX in?
- Royalty Pharma plc (RPRX) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Royalty Pharma plc (RPRX) do?
- Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and dia…